NOVEL SYNTHESIS OF PYRAZOLE-CONTAINING THIOPHENE, 2-ALKYLOXY-PYRIDINE AND THIENO[2,3-d]PYRIMIDINE SCAFFOLDS AS ANALGESIC AGENTS

Nagy M. Khalifa¹,³, Hoda H. Fahmy², Eman S. Nossier³, Abd El-Galil E. Amr⁴ and Rashed N. Herqash⁵

¹Pharmaceutical Chemistry Department, Drug Exploration & Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
²Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Division, National Research Centre, Giza, Egypt
³Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University (Girls), Cairo, Egypt
⁴Applied Organic Chemistry Department, National Research Center, 12622 Giza, Egypt
⁵Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

(Received December 15, 2018; Revised September 30, 2019; Accepted October 14, 2019)

ABSTRACT. A group of trisubstituted pyrazoles containing thiophene, 2-alkyloxy pyridine and thieno[2,3-d]pyrimidine heterocycles were synthesized in a study for possible analgesic agents. The desired products were obtained by reaction of 2-((1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)methylene)malononitrile with sulfur in presence of TEA, followed by treatment with different reagents. Newer products were examined for their analgesic properties, among them, analog 7 showed significant analgesic effects in comparison with reference medicines activity.

KEY WORDS: Trisubstituted pyrazoles, Thiophene, Alkyloxy pyridine, Fused pyrimidine, Analgesic activities

INTRODUCTION

Pyrazole compounds have an interesting therapeutic effect. Due to the large amount of drugs including this heterocyclic compound, the pharmaceutical properties of the ring were the topic of medicinal studies. Celecoxib and its derivatives are analgesic medicines with a pyrazole nucleus (Figure 1). Diverse bioactive molecules are developed by pyrazole derivatives such as antibacterial, anti-inflammatory, antifungal, antiviral, antimicrobial, and anti-hyperglycemic properties [1-10]. Moreover, pyrazole-based heterocycles as thiophenes, 2-alkyloxy pyridines and thieno[2,3-d]pyrimidines have been given more attention due to their useful therapeutic fields including, muscle relaxing, antitumor, anti-depressant, antimicrobial, antidiabetic, anti-tubercular, antioxidant, HIV reverse transcriptase inhibitors and also possess significant vasodilation activities [11-17]. They also demonstrated strong anti-inflammatory action with low GIT toxicity and analgesic impacts [18-24]. In the same way, and in the continuing work on synthesis of biologically active heterocycles based pyrazoles [25-29], we focused in this study on designing of new molecules carrying pyrazole substituents as hybrids with various heterocycles aiming to get potent candidates with analgesic properties.

*Corresponding author. nkhalifa.c@ksu.edu.sa
This work is licensed under the Creative Commons Attribution 4.0 International License
EXPERIMENTAL

Electrothermal device 9100 has identified melting points. Elementary microanalysis using Vario Elemental was acceptable and performed. The spectrophotometer Shimadzu 435 IR was used to operate infrared spectrum (KBr pellets technique). Varian Gemini 500 MHz NMR Spectrophotometer was used for recording $^1$H, $^{13}$C NMR spectra DMSO-$d_6$ with TMS as an internal reference. Hewlett Packard 5988 Spectrometer registered the mass spectrum (70 eV).

Animals

The study included albino mice (25-30 g) and wistar rats (150-200 g). Mice and rats used for this experiment were bought from the animal breeding laboratory, NRC, Egypt. Whole animals have been preserved with free access to animal feed under the lights of 12 hours. Prior to testing, the animals were adapted for a week to the lab environment. In line with the Ethics Committee, the animal protocol was performed of (NRC), Egypt.

Central analgesic activity (hot plate test)

By using hot-plate appliance, the central analgesic effects of the examined compounds were achieved. Twelve groups were collected with 6 animals each. The first group was used as (normal control) and the second group was used as (reference) received the vehicle at a dose of (5 mL/kg) and tramadol (40 mg/kg) orally, respectively. Dose levels of (20 mg/kg) were taken orally to the remaining groups from 3rd to 12th. Within an hour of treatment, mice were placed on a hot plate at 53 ± 0.5 °C separately. On mice lick the fore or hind paw or spring away from the location, the reaction time of the thermal stimulus was determined. After oral administration of tested compounds, the response time was recorded (0, 30, 60 and 90 min). The time off for heat stimulation reaction was 60 s to prevent damaging the tissue of the mouse fingers.

Peripheral analgesic activity (Writhing test)

Acetic acid writhing test was achieved on mice and aspirin was used as a reference control. 72 mice, each with six animals, have been divided into 12 sets. Vehicle (5 mL/kg) and aspirin (150
mg/kg) were used orally for treatment of mice of 1st group (control) and 2nd group (reference). Dose of (20 mg/kg) of the 3rd to 12th groups of mouse was administered orally to the test compound. Writhes were produced after a 30 min dose of intraperitoneal injection of acetic acid (0.7% aqueous acetic acid) at a dosage of (10 mL/kg). Mice were then placed in transparent boxes and the mean number of Writhes was calculated for each group in comparison to control group during 20 min according to the equation:

Protection (%) = [(Control mean - Treated mean)/Control mean] x 100

2-Amino-4-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)thiophene-3-carbonitrile (2)

In ethyl alcohol (50 mL), an equimolar mix (0.03 mol) of both ylidenemalononitrile 1 and sulfur were added and the mix was cooled to 10°C, followed by dropwise addition of TEA (0.03 mol). The reaction mixture was heated for 2 h at 80°C, and cooled afterwards. The solid residues generated were ethanol crystallized. Yield: 67%, m.p. 209-211°C. IR (KBr, cm⁻¹): ν 3368 (NH₂), 2210 (CN). 1H NMR (DMSO-d₆): δ 3.81 (s, 3H, OCH₃), 4.52 (s, 2H, NH), 6.54 (s, 1H, CH-thiophene), 7.02-8.56 (m, 8H, ArH), 9.07 (s, 1H, CH). 13C NMR (DMSO-d₆): δ 56.14, 84.51, 103.58, 113.99, 116.16, 116.28, 117.55, 125.18, 126.35, 128.63, 129.10, 130.67, 131.12, 135.01, 135.94, 140.86, 146.22, 150.38, 161.01, 163.45.

5-Amino-3-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1-(quinolin-2-yl)-1H-pyrazole-4-carbonitrile (3)

In (30 mL) of dry ethanol, an equimolar (0.01 mol) of starting 1 and 2-hydrazinylquinoline were refluxed for 6 h. After cooling, the precipitate formed was purified from MeOH. Yield: 63%, m.p. 210-212°C. IR (KBr, cm⁻¹): ν 3374 (NH₂), 2214 (CN). 1H NMR (DMSO-d₆): δ 3.81 (s, 3H, OCH₃), 7.05-7.99 (m, 14H, H-arom), 8.54 (s, 2H, NH, exch.), 8.96 (s, 1H, CH). 13C NMR (DMSO-d₆): δ 56.72, 92.38, 101.35, 104.56, 113.67, 115.42, 115.64, 117.75, 123.58, 124.89, 125.94, 126.18, 126.87, 128.16, 128.37, 128.92, 129.79, 130.47, 131.08, 135.01, 136.29, 140.95, 143.82, 145.90, 153.72, 157.93, 161.76. MS, m/z (%): 517 (M⁺, 9). Anal. calc'd for C₂₇H₂₃ClN₂O (517.97): C, 76.72; H, 3.89; N, 18.19. Found: C, 76.78; H, 3.87; N, 18.65.

General method for synthesis of 2-alkyloxypyridine-3-carbonitrile derivatives 4a-h

In an appropriate ethyl or methyl alcohol (15 mL) containing (0.003 mol) of potassium hydroxide, a mix of starting 1 (0.003 mol) and aryl ketones (0.003 mol) were stirred at ambient temperature for almost 67 h (monitored by TLC). The produced residue was purified with butanol.

4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methoxy-6-(pyridine-3-yl)pyridine-3-carbonitrile (4a). Yield: 46%, m.p. 234-236°C. IR (KBr, cm⁻¹): ν 2227 (CN). 1H NMR (DMSO-d₆): δ 3.79, 3.81 (2s, 6H, 2OCH₃), 7.01-8.45 (m, 13H, ArH + H-5 pyridine), 8.95 (s, 1H, CH). 13C NMR (DMSO-d₆): δ 55.68, 56.12, 95.01, 102.84, 112.73, 114.58, 115.39, 115.64, 119.22, 120.17, 123.62, 125.34, 126.41, 129.03, 131.10, 134.70, 135.08, 139.24, 140.99, 146.13, 149.26, 150.02, 157.46, 161.01, 161.40. MS, m/z (%): 493 (M⁺, 6). Anal. calc'd for C₂₉H₂₀ClN₂O₂ (493.94): C, 68.08; H, 4.08; N, 7.18. Found: C, 67.91; H, 3.89; N, 7.04.

4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-ethoxy-6-(pyridine-3-yl)pyridine-3-carbonitrile (4b). Yield: 39%, m.p. 182-184°C. IR (KBr, cm⁻¹): ν 2221 (CN). 1H NMR (DMSO-d₆): δ 1.52 (t, 3H, J = 7.2 Hz, CH₃), 3.80 (s, 3H, OCH₃), 4.60 (q, 2H, J = 7.0 Hz, CH₂),

Bull. Chem. Soc. Ethiop. 2019, 33(3)
7.01-8.52 (m, 13H, ArH + H-pyridine), 8.95 (s, 1H, CH). \(^1\)C NMR (DMSO-\(d_6\)): \(\delta\) 14.49, 56.05, 63.12, 94.78, 102.65, 112.80, 114.83, 115.40, 115.69, 118.02, 120.38, 123.55, 125.32, 126.19, 128.67, 131.06, 134.48, 135.01, 138.60, 141.15, 145.85, 147.91, 149.98, 155.16, 157.66, 161.01, 164.25. MS, m/z (\%): 507 (M\(^+\), 4). Anal. calcd for C\(_{25}\)H\(_22\)ClN\(_2\)O\(_2\): C, 68.39; H, 4.20; N, 13.63.

4-(1-(3-Chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methoxy-6-(thiophen-2-yl)-pyridine-3-carbonitrile (4c). Yield: 28%; m.p. 243-245 \(^\circ\)C. IR (KBr, cm\(^{-1}\)) \(\nu\): 2223 (CN). \(^1\)H NMR (DMSO-\(d_6\)): \(\delta\) 3.78, 3.81 (2s, 6H, 2OCH\(_3\)), 7.01-8.45 (m, 12H, ArH + H-5 pyridine), 8.95 (s, 1H, CH). \(^1\)C NMR (DMSO-\(d_6\)): \(\delta\) 55.64, 56.08, 93.89, 104.50, 112.81, 114.63, 115.56, 116.04, 118.21, 125.28, 125.79, 126.16, 127.11, 127.88, 128.46, 130.95, 133.82, 135.01, 139.68, 142.31, 145.76, 153.14, 154.27, 161.01, 163.96. MS, m/z (\%): 498 (M\(^+\), 2). Anal. calcd for C\(_{25}\)H\(_{22}\)ClN\(_2\)O\(_2\): C, 64.99; H, 4.08; N, 11.23; found: C, 64.80; H, 3.68; N, 11.07.

4-(1-(3-Chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-ethoxy-6-(thiophen-2-yl)-pyridine-3-carbonitrile (4d). Yield: 32%; m.p. 257-259 \(^\circ\)C. IR (KBr, cm\(^{-1}\)) \(\nu\): 2219 (CN). \(^1\)H NMR (DMSO-\(d_6\)): \(\delta\) 1.49 (t, 3H, J = 6.8 Hz, CH\(_3\)), 3.81 (s, 3H, OCH\(_3\)), 4.62 (q, 2H, J = 6.8 Hz, CH\(_2\)), 7.01-8.55 (m, 12H, ArH + H-5 pyridine), 8.96 (s, 1H, CH). \(^1\)C NMR (DMSO-\(d_6\)): \(\delta\) 14.52, 55.60, 63.24, 94.17, 104.45, 112.78, 114.71, 115.47, 115.95, 118.34, 124.90, 125.84, 126.10, 127.12, 127.74, 128.54, 131.08, 134.29, 135.01, 140.18, 142.49, 147.02, 152.60, 155.13, 161.01, 164.20. MS, m/z (\%): 513 (M\(^+\), 4). Anal. calcd for C\(_{25}\)H\(_{23}\)ClN\(_2\)O\(_2\): C, 65.55; H, 4.13; N, 10.92; found: C, 65.37; H, 3.98; N, 10.76.

4-(1-(3-Chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)-6-(4-hydroxyphenyl)-2-methoxy-pyridine-3-carbonitrile (4e). Yield: 31%; m.p. 257-259 \(^\circ\)C. IR (KBr, cm\(^{-1}\)) \(\nu\): 2219 (CN). \(^1\)H NMR (DMSO-\(d_6\)): \(\delta\) 1.40 (t, 3H, J = 7.6 Hz, CH\(_3\)), 3.81 (s, 3H, OCH\(_3\)), 4.51 (q, 2H, J = 7.6 Hz, CH\(_2\)), 7.01-8.70 (m, 13H, ArH + H-5 pyridine), 8.95 (s, 1H, CH), 10.45 (s, 1H, OH). \(^1\)C NMR (DMSO-\(d_6\)): \(\delta\) 14.82, 56.04, 63.20, 94.06, 104.56, 112.82, 114.54, 115.27, 115.93, 116.10, 118.31, 125.17, 128.35, 128.90, 129.01, 130.74, 133.87, 135.01, 141.08, 145.97, 157.05, 157.34, 161.01, 164.10. MS, m/z (\%): 523 (M\(^+\), 7). Anal. calcd for C\(_{25}\)H\(_{23}\)ClN\(_2\)O\(_3\): C, 68.90; H, 4.43; N, 10.71; found: C, 68.71; H, 4.25; N, 10.62.

4-(1-(3-Chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methoxy-6-(4-nitrophenyl)-pyridine-3-carbonitrile (4f). Yield: 39%; m.p. 262-264 \(^\circ\)C. IR (KBr, cm\(^{-1}\)) \(\nu\): 3398 (OH), 2226 (CN). \(^1\)H NMR (DMSO-\(d_6\)): \(\delta\) 3.78, 3.81 (2s, 6H, 2OCH\(_3\)), 7.05-8.30 (m, 13H, ArH + H-5 pyridine), 8.95 (s, 1H, CH). \(^1\)C NMR (DMSO-\(d_6\)): \(\delta\) 55.69, 56.15, 93.89, 104.34, 112.83, 114.60, 115.42, 115.90, 118.24, 121.47, 125.37, 126.18, 128.52, 128.68, 130.71, 133.75, 135.01, 141.04, 143.12, 145.85, 147.10, 153.02, 157.23, 161.01, 164.30. MS, m/z (\%): 538 (M\(^+\), 5). Anal. calcd for C\(_{25}\)H\(_{22}\)ClN\(_2\)O\(_4\): C, 64.75; H, 3.75; N, 13.02; found: C, 64.58; H, 3.60; N, 12.89.

4-(1-(3-Chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-ethoxy-6-(4-nitrophenyl)-pyridine-3-carbonitrile (4h). Yield: 33%; m.p. 178-180 \(^\circ\)C. IR (KBr, cm\(^{-1}\)) \(\nu\): 2228 (CN). \(^1\)H NMR

Bull. Chem. Soc. Ethiop. 2019, 33(3)
Synthesis of pyrazole-containing thiophene, 2-alkyloxy-pyridine and one more

(DMSO-d$_6$): δ 1.42 (t, 3H, J = 7.4 Hz, CH$_3$), 3.80 (s, 3H, OCH$_3$), 4.56 (q, 2H, J = 7.4 Hz, CH$_2$), 7.05-8.32 (m, 13H, ArH + H-5 pyridine), 8.95 (s, 1H, CH). $^{13}$C NMR (DMSO-d$_6$): δ 14.76, 56.09, 63.31, 94.15 104.45, 112.80, 114.57, 115.48, 118.20, 121.64, 125.44, 126.10, 128.49, 128.79, 130.62, 134.02, 135.01, 137.56, 140.78, 145.92, 148.16, 150.73, 150.84, 161.01, 168.54.

In a mixture of HCl/AcOH (3:9 mL), starting 4(3H)-pyridazine was refluxed for 3-4 h. The reaction mixture could cool down, the precipitation formed after it was pour into cold water. The solid product separated after being poured into cold water was gathered and dioxan crystallized. The crude product was dried, and dioxan crystallized. Yield 51%, m.p. 161-163 °C. IR, ν: 3470, 3236 (NH), 3195 (NH), 1667 (CO).

N-(4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-3-cyanothiophen-2-yl)-aceta- mide (5)

In (7 mL) of acetic anhydride, starting 2 has been heated for 4 h under reflux. The solid product separated after being poured into cold water was gathered and purified from dioxane. Yield 51%, m.p. 161-163 °C. IR, ν: 3446 (NH), 2218 (CN), 1658 (CO).

General method for preparation of derivatives 7, 8

A solution of starting 2 in (15 mL) of formamide or formic acid was reflux for 3-4 h. After cooling, the solid product was washed and AcOH-crystallized.

5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-2-methylthieno[2,3-d]pyrimidin-4(3H)-one (6)

In a mixture of HCl/AcOH (3:9 mL), starting 2 and/or derivative 5 (0.01 mol) was refluxed for 2 h. The reaction mixture could cool down, the precipitation formed after it was pour in cold water was dried, and dioxan crystallized. Yield 60%, m.p. 192-194 °C. IR, ν: 3205 (NH), 1672 (CO).

General method for preparation of derivatives 7, 8

A solution of starting 2 in (15 mL) of formamide or formic acid was reflux for 3-4 h. After cooling, the solid product was washed and AcOH-crystallized.

5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (7)

In (7 mL) of acetic anhydride, starting 2 has been heated for 4 h under reflux. The solid product separated after being poured into cold water was gathered and purified from dioxane. Yield 57%, m.p. 330 °C. IR, ν: 3195 (NH), 1667 (CO).

5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)thieno[2,3-d]pyrimidin-4(3H)-one (8)

In (7 mL) of acetic anhydride, starting 2 has been heated for 4 h under reflux. The solid product separated after being poured into cold water was gathered and purified from dioxane. Yield 57%, m.p. 330 °C. IR, ν: 3195 (NH), 1667 (CO).

Bull. Chem. Soc. Ethiop. 2019, 33(3)
In absolute ethanol (30 mL) containing (0.5 mL) of TEA, an equimolar mix (0.01 mol) of compound 2 and phenyl isothiocyanate were reflux for 5 h. The solid produced was methanol treated in basic conditions with sulfur to provide 5-amino-4-cyano-3-aryl-pyrazole derivative 3. The later compound showed two different bands at 3374 and 2214 cm\(^{-1}\) belonging to amino and cyano functions, meanwhile \(^1\)H NMR spectrum showed two singlets at δ 3.81 and 8.54 ppm referred to

![Chemical structure](image)

Scheme 1. Synthesis of compounds 2, 3 and 4a-h.

Bull. Chem. Soc. Ethiop. 2019, 33(3)
methoxy and amino protons. Furthermore, the precursor 1 condensed with various aryl ketones according to Michael addition to provide the desired 2-alkyloxy pyridine-3-carbonitriles 4a-h (Scheme 1). The later products exhibited strong bands in the range of 2219-2228 cm\(^{-1}\) referred to nitrile function in the IR spectrum. Also, the appearance of peaks corresponding to alkoxide in \(^1\)H NMR spectrum confirming the cyclization form of pyridine moiety. Moreover, \(^{13}\)C NMR and MS confirmed the carbons at their expected regions and molecular formula of the title products.

The key intermediate 2 was reacted with acetic anhydride to afford acyclic 3-cyanothiophen-2-acetamide derivative 5. Compounds 2 or 5 treated with HCl/AcOH mixture (3:9 mL) to afford the pyrimidinone derivative 6. \(^1\)H NMR spectrum showed peaks for methyl and amino protons at \(\delta\) 2.41, 8.12 ppm besides peaks appeared in the \(^{13}\)C NMR spectrum attributed to methyl and carbonyl groups at \(\delta\) 21.04, 160.14 ppm.

![Scheme 2. Synthesis of compounds 5-9.](image)

The desired thieno[2,3-\(d\)]pyrimidine derivatives 7, 8 could be achieved through cyclization reaction of compound 2 and formamide or formic acid. Compound 7 indicated the disappearance of nitrile band and appearance of new bands for the amino group at 3470, 3236 cm\(^{-1}\) in IR...
spectrum, besides two singlet peaks for H-2 of pyrimidine and amino protons at δ 8.12 and 8.34 ppm respectively in the 1H NMR spectrum. In the same time, compound 8 revealed lack of nitrile function with the appearance of new bands for amino and carbonyl groups.

Furthermore, the key intermediate 2 was reacted with phenyl isothiocyanate to give the corresponding 3-cyanothiophen-2-phenylthioureide derivative 9 (Scheme 2). New bands were shown in the later compound 9 at 3428, 3190 and 2210 cm⁻¹ due to (2NH) and (CN) functions in IR spectra, besides two singlets signals appeared at δ 4.45 and 11.26 ppm assigned to D₂O-exchangeable (2NH) protons in the 1H NMR spectrum.

**Analgesic activity evaluation**

The analgesic profile of compounds 2–9, acquired from hot plate test and acetic acid induced writhing test was performed using the techniques previously mentioned [30,31]. The findings are presented in (Tables 1 and 2).

The compounds tested showed remarkable analgesic effects in the hot plate and writhing assays in mice. Regarding central analgesic activity (hot plate test): The latency of the examined products improved compared to fundamental levels by oral administration. The resulting data revealed 4d, 4e, 4f, 4g, 4h, 6, 7 and 9 derivatives showing significant analgesic activity (70-159 %) increase in pain threshold after 90 min following the administration. Compound 7 which contains the fused pyrimidine moiety showed highest core analgesic characteristics (159.6%) at 90 min, which was statistically equisup to the control drug (174.6%). The central analgesic properties of the active products next 90 min, sorted in descending way, were 159.6, 115.28, 102.1, 93.8, 85.6, 84.2, 80.1, 76.0 and 70.5 % for derivatives 7, 4g, 4e, 4f, 4d, 3, 4, 4h and 9, respectively, comparable to the reference tramadol (Table 1).

Table 1. Central analgesic activity of synthesized compounds in mice.

| Compds | 0 min Reaction time (s) | 30 min Reaction time (s) | Protection (%) | 60 min Reaction time (s) | Protection (%) | 90 min Reaction time (s) | Protection (%) |
|--------|------------------------|------------------------|----------------|------------------------|----------------|------------------------|----------------|
| Control | 12.3±0.04 | 12.8±0.91 | 0 | 14.5±0.45 | 0 | 14.6±0.58 | 0 |
| 2      | 10.3±0.38 | 12.6±1.00 | 9.8 | 15.4±0.81 | 6.2 | 21.1±1.10 | 44.5 |
| 3      | 11.6±0.65 | 12.2±0.97 | 79.3 | 24.0±1.12 | 65.5 | 26.9±2.38 | 84.2 |
| 4a     | 10.4±0.79 | 15.2±2.01 | 19.6 | 18.2±0.94 | 25.5 | 22.4±0.91 | 53.4 |
| 4b     | 11.0±0.38 | 12.9±1.19 | 1.6 | 15.2±1.04 | 4.8 | 20.8±1.57 | 42.4 |
| 4c     | 10.6±0.41 | 13.9±0.42 | 9.4 | 19.2±0.36 | 32.4 | 19.5±1.00 | 33.6 |
| 4d     | 11.1±0.90 | 18.3±0.85 | 44.0 | 22.6±1.35 | 55.9 | 27.1±2.14 | 85.6 |
| 4e     | 10.5±0.54 | 18.5±1.00 | 45.7 | 21.1±2.09 | 45.5 | 29.5±2.42 | 102.1 |
| 4f     | 11.2±0.61 | 19.1±1.12 | 50.4 | 24.0±0.87 | 65.5 | 28.3±0.98 | 93.8 |
| 4g     | 10.7±0.86 | 24.9±0.51 | 96.0 | 28.5±1.45 | 96.6 | 31.5±1.40 | 115.8 |
| 4h     | 12.1±0.57 | 15.8±0.45 | 24.4 | 22.6±0.67 | 55.9 | 25.7±2.05 | 76.0 |
| 5      | 10.1±0.48 | 17.6±1.00 | 38.6 | 25.1±1.00 | 73.1 | 23.1±2.67 | 58.2 |
| 6      | 11.5±0.69 | 15.9±0.56 | 25.2 | 19.3±1.23 | 33.1 | 26.3±1.04 | 80.1 |
| 7      | 10.4±0.82 | 26.1±1.23 | 105.5 | 31.5±0.10 | 117.2 | 37.9±0.37 | 159.6 |
| 8      | 10.0±0.94 | 17.0±1.34 | 33.8 | 20.8±2.05 | 43.4 | 19.8±0.87 | 35.6 |
| 9      | 10.1±0.02 | 20.3±0.73 | 59.8 | 25.4±0.90 | 75.1 | 24.9±2.51 | 70.5 |
| Tramadol | 10.6±0.53 | 29.6±1.57 | 131.2 | 33.0±1.00 | 127.5 | 40.1±2.28 | 174.6 |

* p < 0.05: Statistically significant from control (Dunnett’s test). \( \bar{p} < 0.05 \): statistically significant from tramadol (Dunnett’s test).

According to acetic acid induced writhing test, peripheral analgesic activity was found in all the compounds examined versus acetic acid induced writhing conduct related to vehicle-treated mice. A considerable decrease in the writhing response was noticed in compounds 4e (70.29%),

Bull. Chem. Soc. Ethiop. 2019, 33(3)
4g (75.25) and 7 (82.43%). In addition, the peripheral analgesic impact of pyrimidine analog 7 (82.43%) showed superior to those of aspirin (78.47%) (Table 2, Figure 2).

Table 2. Peripheral analgesic activity of synthesized compounds in mice.

| Compds | No. of writhes /20 min | Protection (%) | Compds | No. of writhes /20 min | Protection (%) |
|--------|-----------------------|----------------|--------|-----------------------|----------------|
| Control       | 80.8±4.5*             | -----          | 4g    | 20.8±1.3*             | 74.25          |
| 2         | 28.4±2.1*             | 64.85         | 4h    | 28.6±2.9*             | 64.60         |
| 3         | 34.6±1.4*             | 57.18         | 5     | 38.2±1.7*             | 52.72         |
| 4a        | 41.2±3.2*             | 49.00         | 6     | 31.5±2.1*             | 61.01         |
| 4b        | 39.8±1.8*             | 50.74         | 7     | 14.2±1.0*             | 82.43         |
| 4c        | 36.5±1.8*             | 54.83         | 8     | 43.6±2.9*             | 46.04         |
| 4d        | 27.1±2.5*             | 66.46         | 9     | 27.3±2.5*             | 66.21         |
| 4e        | 24.0±1.6*             | 70.29         | Aspirin | 17.4±1.6*             | 78.43         |
| 4f        | 23.3±3.3*             | 68.49         |        |                       |                |

Figure 2. Peripheral analgesic activity of the synthesized products 2-9 in mice.

CONCLUSION

New pyrazole derivatives including thiophene, 2-alkyloxy-pyridine and thieno[2,3-d]pyrimidines have been synthesized and analgesical activities and have been performed and discussed. The products acquired inhibited the restriction of acetic acid and the response of hot plate device relative to conventional aspirin control. Our results suggest that it is favorable to analgesic activity to incorporate substituted pyridine and fused thieno[2,3-d]pyrimidinemoieties with pyrazole backbone.
ACKNOWLEDGMENTS

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this research through the Research Group No. RGP-320.

REFERENCES

1. Bekhit, A.A.; Abdel-Rahman, H.M.; Guemei, A.A. Synthesis and biological evaluation of some hydroxypyrazole derivatives as anti-inflammatory antimicrobial agents. *Arch. Pharm.* 2006, 339, 81-87.

2. El-Sabbagh, O.I.; Baraka, M.M.; Ibrahim, S.M.; Pannecoque, C.; Andrei, G.; Snoeck, R.; Balzarini, J.; Rashad, A.A. Synthesis and antiviral activity of new pyrazole and thiazole derivatives. *Eur. J. Med. Chem.* 2009, 44, 3746-3753.

3. Koca, I.; Ozgur, A.; Coskun, K.A.; Tutar, Y. Synthesis and anticancer activity of acyl thioureas bearing pyrazole moiety. *Bioorg. Med. Chem.* 2013, 21, 3859-3865.

4. Li, Y.; Zhang, H.Q.; Liu, J.; Yang, X.P.; Liu, Z.J. Stereoselective synthesis and antifungal activities of 1-alpha-(methoxyimino) benzeneacetate derivatives containing 1,3,5-substituted pyrazole ring. *J. Agric. Food Chem.* 2006, 54, 3636-3640.

5. Lv, P.C.; Li, H.Q.; Sun, J.; Zhou, Y.; Zhu, H.L. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. *Bioorg. Med. Chem.* 2010, 18, 4606-4614.

6. Alegaon, S.G.; Hirpara, M.B.; Alagawadi, K.R.; Jalalpure, S.S.; Salve, P.S.; Kumbar, V.M. Synthesis and biological evaluation of 1,3,4-trisubstituted pyrazole analogues as anti-mycobacterial agents. *Med. Chem. Res.* 2017, 26, 1127-1138.

7. Kundu, P.; Chattopadhyay, N. Interaction of a bioactive pyrazole derivative with calf thymus DNA: deciphering the mode of binding by multi-spectroscopic and molecular docking investigations. *J. Photochem. Photobiol. B Biol.* 2017, 173, 485-492.

8. Wang, Y.; Cheng, F.X.; Yuan, X.L.; Tang, W.J.; Shi, J.B.; Liao, C.Z.; Liu, X.H. Dihydropyrazole derivatives as telomerase inhibitors: structure-based design, synthesis, and anticancer evaluation in vitro and in vivo. *Eur. J. Med. Chem.* 2016, 112, 231-251.

9. Chen, Y.Y.; Wu, X.Q.; Tang, W.J.; Shi, J.B.; Li, J.; Liu, X.H. Novel dihydropyrazolechromen: design and modulates hTERT inhibition proliferation of MGC-803. *Eur. J. Med. Chem.* 2016, 110, 65-75.

10. Ribeiro, N. New Cu(II) complexes with pyrazolyl derived Schiff base ligands: Synthesis and biological evaluation. *J. Inorg. Biochem.* 2017, 174, 63-75.

11. Verma, G.; Chashoo, G.; Ali, A.; Khan, M.F.; Akhtar, W.; Ali, I.; Akhtar, M.; Alam, M.M.; Shaquiquzzaman, M. Synthesis of pyrazole acrylic acid based oxadiazole and amide derivatives as antimalarial and anticancer agents. *Bioorg. Chem.* 2018, 77, 106-124.

12. Malladi, S.; Isloor, A.M.; Isloor, S.; Akhila, D.S.; Fun, H.-K. Synthesis, characterization and antibacterial activity of some new pyrazole based Schiff bases. *Arabian J Chem.* 2013, 6, 335-340.

13. Gouda, M.A.; Fakhr Eldien, H.; Girges, M.M.; Berghot, M.A. Synthesis and antitumor evaluation of thiophene based azo dyes incorporating pyrazolone moiety. *J Saudi Chem Soc.* 2016, 20, 151-157.

14. Aly, H.M.; Saleh, N.M.; Elhady, H.A. Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrene as potential antimicrobial agents. *Eur. J. Med. Chem.* 2011, 46, 4566-4572.

15. Xu, Z.; Gao, C.; Ren, Q.C.; Song, X.F.; Feng, L.S.; Lv, Z.S. Recent advances of pyrazole-containing derivatives as anti-tubercular agents. *Eur. J. Med. Chem.* 2017, 139, 429-440.

16. Abdellatif, K.R.A.; Fadaly, W.A.A.; Kamel, G.M.; Elshaier, Y.A.M.; El-Magd, M.A.
Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors. *Bioorg. Chem.* **2019**, *82*, 86-99.

17. Alegaon, S.G.; Alagawadi, K.R.; Garg, M.K.; Dushyant, K.; Vinod, D. 1,3,4-Trisubstituted pyrazole analogues as promising anti-inflammatory agents. *Bioorg. Chem.* **2014**, *54*, 51-59.

18. Ragab, F.A.; Abdel Gawad, N.M.; Georgeoy, H.H.; Said, M.F. Synthesis of novel 1,3,4-trisubstituted pyrazoles as anti-inflammatory and analgesic agents. *Eur. J. Med. Chem.* **2013**, *63*, 645-654.

19. Vijesh, A.M.; Isloor, A.M.; Shetty, P.; Sundershan, S.; Fun, H.K. New pyrazole derivatives containing 1,2,4-triazoles and benzoazoles as potent antimicrobial and analgesic agents. *Eur. J. Med. Chem.* **2013**, *62*, 410-415.

20. Abdellatif, K.; Abdelall, E.; Bakr, R. Nitric oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents. *Curr. Top. Med. Chem.* **2017**, *17*, 941-955.

21. Bakr, R.B.; Azouz, A.A., Abdellatif, K.R. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo [3,4-d]pyrimidine derivatives. *J. Enzyme Inhib. Med. Chem.* **2016**, *31*, 6-12.

22. Amir, M.; Kumar, S. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of 3, 5-dimethyl pyrazoles, 3-methyl pyrazol-5-ones and 3,5-disubstituted pyrazolines, *Indian J. Chem.* **2005**, *44B*, 2532-2537.

23. Prabhudeva, M.G.; Bharath, S.; Kumar, A.D.; Naveen, S.; Lokanath, N.K.; Mylarappa, B.N.; Kumar, K.A. Design and environmentally benign synthesis of novel thiophene appended pyrazole analogues as anti-inflammatory and radical scavenging agents: Crystallographic, in silico modeling, docking and SAR characterization. *Bioorg. Chem.* **2017**, *73*, 109-120.

24. Mohamed, L.W.; Shaaban, M.A.; Zaher, A.F.; Alhamaky, S.M.; Elsahar, A.M. Synthesis of new pyrazoles and pyrazolo [3,4-b] pyridines as anti-inflammatory agents by inhibition of COX-2 enzyme. *Bioorg. Chem.* **2019**, *83*, 47-54.

25. Nossier, E.S.; Fahmy, H.H.; Khalifa, N.M.; El-Eraky, W.I.; Basit, M.A. Design and synthesis of novel pyrazole-substituted different nitrogenous heterocyclic ring systems as potential anti-Inflammatory agents. *Molecules* **2017**, *22*, 512-528.

26. Fahmy, H.H.; Khalifa, N.M.; Ismail, M.M.; El-Sahrawy, H.M.; Nossier, E.S. Biological validation of novel polysubstituted pyrazole candidates with in vitro anticancer activities. *Molecules* **2016**, *21*, 271-284.

27. Khalifa, N.M.; Srour, A.M.; Abd El-Karim, S.S.; Saleh, D.O.; Al-Omar, M.A. Synthesis and 2D-QSAR study of active benzofuran-based vasodilators. *Molecules* **2016**, *22*, 1820-1835.

28. Nossier, E.S.; Abd El-Karim, S.S.; Khalifa, N.M.; El-Sayed, A.S.; Hassan, E.S.; El-Hallouty, S. M. Kinase inhibitory activities and molecular docking of a novel series of anticancer pyrazole derivatives. *Molecules* **2018**, *23*, 3074.

29. Ismail, F.M.; Khalifa, N.M.; Fahmy, H.H.; Nossier, E.S.; Abdullad, M.M. Design, docking, and synthesis of some new pyrazoline and pyranopyrazole derivatives as anti-inflammatory agents. *J. Heterocyclic Chem.* **2014**, *51*, 450-458.

30. Turner, R. *Screening Methods in Pharmacology*, Academic Press: New York; **1965**, pp 101-113.

31. Collier, H.O.J.; Dinneen, L.C.; Johnson, C.A.; Schneider, C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. *Br. J. Pharmacol. Chemother.* **1968**, *32*, 295-310.